The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulating the selectivity of an anesthetic for an anesthetic-sensitive receptor by altering or modifying the anesthetic to have higher or lower water solubility. The invention further provides methods of inducing anesthesia in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods.

The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulating the selectivity of an anesthetic for an anesthetic-sensitive receptor by altering or modifying the anesthetic to have higher or lower water solubility. The invention further provides methods of inducing anesthesia in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods.

Methods and systems for performing 3-D LIDAR measurements of objects simultaneously illuminated by two or more beams of light in the far field are described herein. A 3-D LIDAR based measurement device simultaneously emits at least two beams of light into a three dimensional environment from different locations. A portion of the three dimensional environment is simultaneously illuminated by the two or more light beams at a distance of at least five meters from the LIDAR device. However, the two or more light beams do not overlap at a distance less than five meters from the LIDAR device. The beams of light are slightly divergent, having highest intensity at the device and steadily lower intensity further away. By overlapping illumination beams in the far field, but not near the LIDAR device, overall intensity is maintained at moderate levels throughout the field of view of the LIDAR device.

A treatment system and method includes use of a chemical facilitator to provide a result-effective event against one or more negative therapeutic effects related to exposing to a light output a skin portion including a condition treatable in whole or in part with light. In one exemplary embodiment for skin treatment including tattoo removal, perfluorodecalin is used to inhibit or resolve whitening, for example to speed a laser therapy session.

A treatment system and method includes use of a chemical facilitator to provide a result-effective event against one or more negative therapeutic effects related to exposing to a light output a skin portion including a condition treatable in whole or in part with light. In one exemplary embodiment for skin treatment including tattoo removal, perfluorodecalin is used to inhibit or resolve whitening, for example to speed a laser therapy session.

The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulating the selectivity of an anesthetic for an anesthetic-sensitive receptor by altering or modifying the anesthetic to have higher or lower water solubility. The invention further provides methods of inducing anesthesia in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods.

The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulating the selectivity of an anesthetic for an anesthetic-sensitive receptor by altering or modifying the anesthetic to have higher or lower water solubility. The invention further provides methods of inducing anesthesia in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods.

The invention relates to a process for producing a compound comprising an .sup.18F-difluoromethyl group or a compound comprising an .sup.18F-difluoromethylene group, which process comprises contacting a compound comprising a nucleophilic group with .sup.18F-difluorocarbene. The invention also relates to a compound of Formula (I). Compounds comprising an .sup.18F-difluoromethyl group or an .sup.18F-difluoromethylene group are also the subject of the present invention.

The invention relates to a process for producing a compound comprising an .sup.18F-difluoromethyl group or a compound comprising an .sup.18F-difluoromethylene group, which process comprises contacting a compound comprising a nucleophilic group with .sup.18F-difluorocarbene. The invention also relates to a compound of Formula (I). Compounds comprising an .sup.18F-difluoromethyl group or an .sup.18F-difluoromethylene group are also the subject of the present invention.

The present invention relates to fluorinated and alkylated bile acids.